- New Cystic Fibrosis Drug — WVU Health Report
- DEA Targets Gas Station, Jeweler in 29-State Synthetic Drug Sweep – Los Angeles Times
- News in Brief: ADA Father of the Year Awards Announced
- Elk County Jail Experiences Overcrowding
- Are There Any Doctors in Michigan Who Prescribe Methadone for Addiction?
- Defibrillator After Heart Attack? What Does That Mean?
- Residential Psychiatric Treatment for Young Adults in New England?
- Addiction Treatment Center
- Prescription Drug Abuse a Problem – San Angelo Standard Times
- Drug Rehab Centers Howard County Call 410-777-5692 for Help Now MD
- Who’s Know About Drug Addiction?
- Addiction in the Heartland, How Drugs and Alcohol Are Poisoning Our Youth
- Prescription Drug Abuse a Problem – San Angelo Standard Times
Beta-Blocker Clears Infancy Hemangiomas
Beta-Blocker Clears Infancy Hemangiomas
Filed under: drug treatment programs in maryland
After 24 weeks of continuous therapy, clearance rates were 60.4% with propranolol compared with 3.6% in the placebo group, reported Christine Léauté-Labrèze, MD, and colleagues at the American Academy of Dermatology meeting. Three other propranolol …
Read more on MedPage Today
Researchers discover how to shutdown cancer's powerful master protein
Filed under: drug treatment programs in maryland
In fact, the findings in this study were inspired from preclinical testing of two Bcl6-targeting agents that Dr. Melnick and his Weill Cornell colleagues have developed to treat DLBCLs. These experimental drugs are RI-BPI, a peptide mimic, and the …
Read more on EurekAlert (press release)
KYTHERA Biopharmaceuticals, Inc. Announces Positive Interim Results from …
Filed under: drug treatment programs in maryland
“In my practice, patients often request a non-surgical way to treat their submental fat, or undesirable double chin,” said investigator Susan Weinkle, MD, FAAD, a board certified dermatologist and affiliate clinical professor at the University of South …
Read more on Business Wire (press release)
Roche's trastuzumab emtansine receives FDA approval
Filed under: drug treatment programs in maryland
“Trastuzumab emtansine is an antibody-drug conjugate representing a completely new way to treat HER2-positive metastatic breast cancer, and it helped people in the EMILIA study live nearly six months longer,” said Hal Barron, M.D., Roche's chief …
Read more on Malaya